ֱ

COVID vs Head, Heart, and Heparin; Afib Screening Flop; Phone Triage Dangerous?

— Recent developments of interest in cardiovascular medicine

MedpageToday
Electrocardiogram on top and bottom of image with CardioBreak in the center.

binds to cells at a site adjacent to ACE2, the portal for SARS-CoV-2 infection, and "potently" blocks the virus, which could open up therapy options. (Cell)

The heightened focus on post-viral effects is what's really novel about , a piece in The Atlantic suggests.

Nearly , with "exceedingly high" 34% in-hospital mortality, a meta-analysis showed. (Neurology)

Opportunistic (Afib) in seniors at primary care visits didn't actually increase the detection rate in a pragmatic randomized trial in the Netherlands. (The BMJ)

Johns Hopkins Hospital turned its interactive gaming room for stroke rehabilitation into a space during the COVID-19 lockdown.

improved, especially for women, from 2008 to 2017. (Circulation)

Sept. 21 marked the 60th anniversary of the first successful implant. (The Oregonian)

, "a giant in modern cardiology," died last week at age 81. (Cardiovascular Business)

Semi-automatic phone triage systems used during out-of-office hours of patients with acute coronary syndrome or other life-threatening events. (Open Heart)

Event risk with suggest it might be better to intervene before middle age and think of akin to "pack-years" of smoking. (Journal of the American College of Cardiology [JACC])

had worse prognoses than their white peers even after achieving NT-proBNP-based treatment goals, according to a study in Circulation.

improved substantially with contemporary drug-eluting stents but still occurs in a of patients. (JACC)

Awareness that heart disease is the leading cause of death among women from 2009 to 2019, particularly for minorities and younger women. (Circulation)

The absorbable for cardiac implantable devices could be considered cost-effectiveness at $112,603 per quality-adjusted life-year gained. (Circulation: Arrhythmia and Electrophysiology)

The second-generation got FDA clearance, Acutus Medical announced.

Abbott said its next-generation got the greenlight from European regulators.

The British National Institute for Health and Care Excellence issued a positive recommendation for as familial chylomicronemia syndrome therapy, Akcea announced.

wasn't better than conventional CRT for electrical dyssynchrony in a small trial reported on the medRxiv preprint server.

from human-induced pluripotent stem cell-derived cardiac cells improved MI recovery in pigs. (BioWorld)